AdvisorShares Psychedelics ETF
Price through Nov 16, 2026 · Flows through unavailable. Figures use the latest available records, not a live quote. Fund details retrieved Nov 16, 2026. Holdings snapshot retrieved Nov 16, 2026.
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
PSIL price
Table
| Date | PSIL close |
|---|---|
| Oct 16, 2026 | $19.90 |
| Oct 19, 2026 | $20.17 |
| Oct 20, 2026 | $21.08 |
| Oct 21, 2026 | $21.02 |
| Oct 22, 2026 | $20.93 |
| Oct 23, 2026 | $20.64 |
| Oct 26, 2026 | $20.67 |
| Oct 27, 2026 | $21.02 |
| Oct 28, 2026 | $21.45 |
| Oct 29, 2026 | $21.60 |
| Oct 30, 2026 | $21.00 |
| Nov 2, 2026 | $19.08 |
| Nov 3, 2026 | $19.51 |
| Nov 4, 2026 | $19.66 |
| Nov 5, 2026 | $18.65 |
| Nov 6, 2026 | $19.39 |
| Nov 9, 2026 | $20.23 |
| Nov 10, 2026 | $19.98 |
| Nov 11, 2026 | $20.07 |
| Nov 12, 2026 | $19.40 |
| Nov 13, 2026 | $19.23 |
| Nov 16, 2026 | $18.17 |
Recent fund-flow records are unavailable, while the price has returned +5.8% so far this year. At 1.28% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | DFTXDefinium Therapeutics | 11.63% | $30.16 | -6.0% | ||
| 2 | CMPSCOMPASS PATHWAYS | 10.37% | $8.27 | -8.2% | ||
| 3 | HELPCybin | 7.75% | $7.67 | -13.5% | ||
| 4 | LLYELI LILLY | 6.43% | $1431.67 | -0.8% | ||
| 5 | ABBVABBVIE | 5.74% | $294.55 | -0.2% | ||
| 6 | NBIXNEUROCRINE BIOSCIENCES | 5.83% | $165.31 | -1.2% | ||
| 7 | RLMDRELMADA THERAPEUTICS | 6.16% | $3.61 | -14.3% | ||
| 8 | SPTXSEAPORT THERAPEUTICS INC | 5.06% | $19.12 | -4.3% | ||
| 9 | JNJJOHNSON & JOHNSON | 4.72% | $282.55 | -1.1% | ||
| 10 | ANROALTO NEUROSCIENCE INC | 5.06% | $27.12 | -8.2% | ||
| 11 | GHRSGH RESEARCH | 4.34% | $18.75 | -1.8% | ||
| 12 | NRXPNRX PHARMACEUTICALS | 3.89% | $2.15 | -1.8% | ||
| 13 | STIMNEURONETICS | 3.45% | $1.25 | -10.1% | ||
| 14 | DRUGBRIGHT MINDS BIOSCIENCES | 2.52% | $22.61 | -2.2% | ||
| 15 | PBMPSYENCE BIOMEDICAL LTD | 1.83% | $2.83 | -10.0% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.
Sign in to see all 25Sector weights
- Healthcare100%
- Health Technology95.32%
- Health Services3.77%
- Other1.61%
- Mutual fund0.91%
Show as table
| Item | Value (%) |
|---|---|
| Healthcare | 100% |
| Health Technology | 95.32% |
| Health Services | 3.77% |
| Other | 1.61% |
| Mutual fund | 0.91% |
Country weights
- United States70.32%
- Canada14.17%
- United Kingdom10.36%
- Other9.58%
- Germany5.22%
- Ireland4.35%
- Australia0.8%
Show as table
| Item | Value (%) |
|---|---|
| United States | 70.32% |
| Canada | 14.17% |
| United Kingdom | 10.36% |
| Other | 9.58% |
| Germany | 5.22% |
| Ireland | 4.35% |
| Australia | 0.8% |
| 1 week | -9.1% |
| 1 month | -8.7% |
| 3 months | -28.1% |
| 6 months | -9.0% |
| YTD | +5.8% |
| 1 year | — |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | — |
| 3 months | — |
| YTD | — |
| 1 year | — |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 11.6% of the book; the top ten carry 69%. Spread across 25+ names, it behaves like roughly 16 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| LLY ELI LILLY | $43M | $45M |
| JNJ JOHNSON & JOHNSON | $6M | $7M |
| ABBV ABBVIE | $4M | $4M |
| NBIX NEUROCRINE BIOSCIENCES | $965,247 | $12,455 |
| HELP Cybin | $284,079 | $382,251 |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat PSIL on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.6B | +$917M | -125bp on fee · 8114× the assets · +$917M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -125bp on fee · 3575× the assets · +$199M in over the month | Head-to-head |
| IJH iShares Core S&P Mid-Cap ETF | 0.05% | $123.7B | +$109M | -123bp on fee · 24102× the assets · +$109M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $34B | +$587M | -124bp on fee · 6625× the assets · +$587M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$422M | -124bp on fee · 4625× the assets · +$422M in over the month | Head-to-head |